1249 adult and adolescent patients were included in 2 identically designed double-blind, randomized, vehicle-controlled trials.1

In both studies, patients were randomized to monotherapy with OPZELURA or vehicle BID applied for 8 weeks.1

Key inclusion criteria1,2:
  • Affected BSA of 3%-20%
  • ≥12 years of age
  • IGA score of 2 or 3*
  • Diagnosis of AD ≥2 years

*Severity scale of 0 to 4.1

AD=atopic dermatitis; BID=twice daily; BSA=body surface area; EASI=Eczema Area and Severity Index; IGA=Investigator's Global Assessment; IGA-TS=Investigator’s Global Assessment Treatment Success; NRS=numeric rating scale.

In the clinical trials, which included patients ≥12 years of age1:
Affected BSA

was 3% to 20% (mean ~10%)1

Affected BSA was
3% to 20% (mean ~10%)1

of patients had facial involvement at baseline1

39% of patients had facial
involvement at baseline

*Patients had a baseline IGA score of 2 to 3 on a severity scale of 0 to 4.1

Itch NRS=7-day average of the worst level of itch intensity in the last 24 hours, measured on a scale of 0 to 10.1,2

AD=atopic dermatitis; BSA=body surface area; IGA=Investigator's Global Assessment; NRS=numeric rating scale.

See skin clearance results >

References: 1. Opzelura. Prescribing Information. Incyte Corporation; 2021. 2. Papp K, Szepietowski JC, Kircik L, et al. Efficacy and safety of ruxolitinib cream for the treatment of atopic dermatitis: results from 2 phase 3, randomized, double-blind studies. J Am Acad Dermatol. Published online May 3, 2021. doi:10.1016/j.jaad.2021.04.085.